Skip to main content
SpringerLink
Log in

Role of Mitoxantrone, High-Dose Cytosine Arabinoside, and Recombinant Human GM-CSF in Aggressive Non-Hodgkin’s Lymphoma

  • Conference paper
Acute Leukemias

Part of the book series: Haematology and Blood Transfusion / Hämatologie und Bluttransfusion ((HAEMATOLOGY,volume 34))

  • 78 Accesses

Abstract

The activity of mitoxantrone in patients with pretreated aggressive non-Hodgkin’s lymphoma (NHL) has been demonstrated in several phase II studies [1–3]. In a previous phase II trial, the present authors investigated the efficacy of mitoxantrone combined with cytarabine (Ara-C) in conventional doses for patients with refractory disease [4], but the response rates did not seem to have improved as compared with mitoxantrone alone. Encouraging results have been reported on the use of high-dose Ara-C alone in relapsed NHL [5–7]. In patients with refractory acute leukemia, the combination of high-dose Ara-C and mitoxantrone has been shown to be active [8, 9]. We have initiated a series of studies with this combination for refractory NHL.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Coltmann CA Jr, McDaniel TM, Balcerzak SP et al. (1982) Mitoxantrone hydrochloride in lymphoma. Cancer Treat Rev 10: 73–76

    Article  Google Scholar 

  2. Gams RA, Steinberg J, Posner L (1984) Mitoxantrone in malignant lymphoma. Sem-in Oncol 1 [Suppl] 47–49

    Google Scholar 

  3. Shenkenberg TD, Von Hoff DD (1986) Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med 105: 67–81

    PubMed  CAS  Google Scholar 

  4. Ho AD, Dörken B, Hunstein W (1985) Mitoxantrone Monotherapie and in Kombination mit Cytosin-Arabinosid bei refraktären Hodgkin and Non-Hodgkin-Lymphomen. Cancer Res Clin Oncol 111: 105

    Article  Google Scholar 

  5. Kantarjian H, Barlogie B, Plunkett Wet al. (1983) High dose cytosine arabinoside in non-Hodgkin’s lymphoma. J Clin Oncol 1: 689–694

    PubMed  CAS  Google Scholar 

  6. Shipp MA, Takvorian RC, Canellos GP (1984) High-dose cytosine arabinoside: active agent in treatment of non-Hodgkin’s lymphoma. Am J Med 77: 845–850

    Article  PubMed  CAS  Google Scholar 

  7. Adelstein DJ, Lazarus HM, Hines JD et al. (1985) High-dose cytosine arabinoside in previously treated patients with poor prognosis non-Hodgkin’s lymphoma. Cancer 56: 1493–1496

    Article  PubMed  CAS  Google Scholar 

  8. Hiddemann W, Kreutzmann H, Straif K. Ludwig WD, Mertelsmann R, DonjuijsenAnt R, Lengfelder E, Arlin Z, Büchner T (1987) High-dose cytosine-arabinoside and mitoxantrone. A highly effective regimen in refractory adult acute myeloid leukemia. Blood 69: 744–749

    PubMed  CAS  Google Scholar 

  9. Hiddemann W, Büchner T, Heil G, Schumacher K, Diedrich H, Maschmeyer G, Ho AD, Planker M, Gerith-Stolzenburg S, Donjuijsen-Ant R, Lengfelder E, Hoelzer D (1990) Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone ( HAM ). Leukemia 4: 637–640

    PubMed  CAS  Google Scholar 

  10. Ho AD, Del Valle F, Ruckle H, Schwammborn J, Schlimok G, Hiddemann W, Meusers P, Dörken B, Hunstein W (1989) Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin’s lymphoma. Cancer 664: 1388–1392

    Article  Google Scholar 

  11. The non-Hodgkin’s Lymphoma Pathologic Classification Project (1982) National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. Cancer 49: 2112–2123

    Article  Google Scholar 

  12. Armitage JO, Dick FR, Corder MP et al. (1982) Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine, and prednisone ( CHOP ). Cancer 50: 1695–1702

    Article  PubMed  CAS  Google Scholar 

  13. Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ (1982) IMVP-16: An effective regimen of patients with lymphoma who have relapses after initial combination chemotherapy. Blood 60: 693–697

    PubMed  CAS  Google Scholar 

  14. Laurence J, Coleman M, Allen SL, Silver RT, Pasmantier M (1982) Combination chemotherapy of advanced diffuse histiocytic lymphoma with six-drug COP-BLAM regimen. Ann Intern Med 97: 190–195

    PubMed  CAS  Google Scholar 

  15. Thiel E, Gerhartz HH, Brittinger G (1988) Response-adapted COP-BLAM/IMVP-16 chemotherapy for advanced stage aggressive non-Hodgkin’s lymphoma. Proc Am Soc Clin Oncol 7: 244

    Google Scholar 

  16. Fisher RI, De Vita VT Jr., Hubbard SM et al. (1983) Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med 98: 304–309

    PubMed  CAS  Google Scholar 

  17. Klimo P, Connors JM (1985) MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 102: 596–602

    PubMed  CAS  Google Scholar 

  18. Skarin AT, Canellos GP, Rosenthal DS et al. (1983) Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high-dose methotrexate alternating with standard agents ( M-BACOD ). J Clin Oncol 1: 91–97

    PubMed  CAS  Google Scholar 

  19. Ho AD, Del Valle F, Engelhard M, Hiddemann W, Rückle H, Schlimok G, Haas R, Thiel E, Andrcesen R, Fiedler W, Frisch J, Schulz G, Hunstein W (1990) Mitoxantrone/high-dose Ara-C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin’s lymphoma. Cancer 66: 423–430

    Article  PubMed  CAS  Google Scholar 

  20. Miller AB, Hoogstraten B, Staquet M et al. (1981) Reporting results of cancer treatment. Cancer 47: 207–214

    Article  PubMed  CAS  Google Scholar 

  21. Heinz R, Dittrich CH, Ludwig H et al. (1986) Results of a new combination chemotherapy (etoposide-ifosphamide-mitoxantrone) in advanced NHL. Cancer Res Clin Oncol 111: [Suppl] 38

    Article  Google Scholar 

  22. Landys KE (1988) Mitoxantrone in combination with sterecyte (NOSTE) in treatment of unfavorable non-Hodgkin’s lymphoma. Invest New Drugs 6: 105–113

    Article  PubMed  CAS  Google Scholar 

  23. Coiffier B, Gisselbrecht C, Vose J, Tilly H, Herbrecht R, Bosly A, Armitage JO (1991) Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 9: 211–219

    PubMed  CAS  Google Scholar 

  24. Hoskins PJ, Ng V, Spinelli J, Klimo P, Connors JM (1991) Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B. J Clin Oncol 9: 220–226

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Heidelberg, Heidelberg, Germany

    A. D. Ho, R. Haas & W. Hunstein

  2. Northeastern Ontario Regional Cancer Centre, 41 Ramsey Lake Road, Sudbury, Ontario, P3E 5J2, Canada

    A. D. Ho

  3. Städtische Kliniken Oldenburg, Oldenburg, Germany

    F. Del Valle

  4. Department of Internal Medicine, University of Essen, Essen, Germany

    M. Engelhard

  5. Department of Internal Medicine, University of Münster, Münster, Germany

    W. Hiddemann

  6. Department of Internal Medicine, University of Würzburg, Würzburg, Germany

    H. Rückle

  7. Zentralklinikum Augsburg, Augsburg, Germany

    G. Schlimok

  8. Department of Internal Medicine, Klinikum Steglitz, University of Berlin, Berlin, Germany

    E. Thiel

  9. Department of Internal Medicine, University of Freiburg, Freiburg, Germany

    R. Andreesen

  10. Department of Oncology and Hematology, University of Hamburg, Hamburg, Germany

    W. Fiedler

Authors
  1. A. D. Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Del Valle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Engelhard
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W. Hiddemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. Rückle
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Schlimok
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E. Thiel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R. Andreesen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. W. Fiedler
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. W. Hunstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, University of Münster, Albert-Schweitzer-Straße 33, D-4400, Münster, Federal Republic of Germany

    W. Hiddemann , T. Büchner  & B. Wörmann ,  & 

  2. M. D. Anderson Cancer Center, University of Texas, 1515 Holocombe Boulevard, 77030, Houston, TX, USA

    W. Plunkett , M. Keating  & M. Andreeff ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Ho, A.D. et al. (1992). Role of Mitoxantrone, High-Dose Cytosine Arabinoside, and Recombinant Human GM-CSF in Aggressive Non-Hodgkin’s Lymphoma. In: Hiddemann, W., Büchner, T., Wörmann, B., Plunkett, W., Keating, M., Andreeff, M. (eds) Acute Leukemias. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 34. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76591-9_112

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-76591-9_112

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-53949-0

  • Online ISBN: 978-3-642-76591-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation